Phase out knockoff versions of Lilly obesity drug, FDA says
FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...
Competition will make weight-loss drugs better, cheaper and bigger
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...
What's next for GLP-1 weight-loss drugs in 2025?
GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY ...
HealthPrep on MSN13h
Top Ten Pros And Cons Of Ozempic You Need To Know Now
Ozempic, a brand name for semaglutide, has gained significant attention in the medical community and among patients for its ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Retail investors buy Novo dip after disappointing weight-loss drug data
U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...
Zacks.com on MSN17h
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
NVO’s success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. Wegovy is a ...
ENDPOINTS NEWS19h
Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?
Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...
Investing20h
Novo Nordisk shares rally despite setback in obesity drug trial results
Investing.com -- Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following ...